. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Daniel Junius, President and CEO, will present at the upcoming 31
Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 8:00 am PT on January 7, 2013 and will include information about IMGN289, which is on track to become the fourth wholly owned ImmunoGen compound to advance into clinical testing.
A webcast of this presentation will be accessible live through the “Investor Information” section of the Company’s website,
; a replay of the presentation will be available at the same location for two weeks.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its TAP technology together with the Company’s expertise in monoclonal antibodies and tumor biology. A TAP compound uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's purpose-developed cancer-killing agents specifically to tumor cells. Ten TAP compounds are now in clinical testing, of which three are wholly owned by the Company. Marketing applications for trastuzumab emtansine (T-DM1), the most advanced compound using ImmunoGen's TAP technology, are under review in the US and Europe. Roche is developing this compound globally under an agreement between ImmunoGen and Genentech, a member of the Roche Group. More information about ImmunoGen can be found at